Becton Dickinson Price to Free Cash Flow Ratio 2012-2026 | BDX
Historical price to free cash flow ratio values for Becton Dickinson (BDX) since 2012.
| Becton Dickinson Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-09-16 | 181.85 | 15.99 | |
| 2026-06-30 | 150.44 | $11.37 | 13.23 |
| 2026-03-31 | 155.21 | $12.22 | 12.70 |
| 2025-12-31 | 149.66 | $9.15 | 16.36 |
| 2025-09-30 | 143.56 | $9.25 | 15.51 |
| 2025-06-30 | 131.40 | $7.17 | 18.32 |
| 2025-03-31 | 173.69 | $7.80 | 22.26 |
| 2024-12-31 | 171.25 | $10.21 | 16.78 |
| 2024-09-30 | 181.13 | $10.72 | 16.90 |
| 2024-06-30 | 174.86 | $11.28 | 15.51 |
| 2024-03-31 | 184.41 | $10.51 | 17.55 |
| 2023-12-31 | 180.98 | $9.20 | 19.66 |
| 2023-09-30 | 191.11 | $7.34 | 26.05 |
| 2023-06-30 | 194.49 | $6.06 | 32.11 |
| 2023-03-31 | 181.70 | $4.45 | 40.82 |
| 2022-12-31 | 185.94 | $4.67 | 39.80 |
| 2022-09-30 | 162.33 | $5.21 | 31.14 |
| 2022-06-30 | 178.99 | $4.25 | 42.12 |
| 2022-03-31 | 187.78 | $3.91 | 47.99 |
| 2021-12-31 | 176.95 | $6.86 | 25.80 |
| 2021-09-30 | 172.36 | $10.04 | 17.17 |
| 2021-06-30 | 169.96 | $11.27 | 15.09 |
| 2021-03-31 | 169.35 | $12.33 | 13.73 |
| 2020-12-31 | 173.68 | $10.10 | 17.19 |
| 2020-09-30 | 160.95 | $7.68 | 20.97 |
| 2020-06-30 | 164.95 | $8.80 | 18.74 |
| 2020-03-31 | 157.88 | $9.08 | 17.38 |
| 2019-12-31 | 186.26 | $10.32 | 18.06 |
| 2019-09-30 | 172.72 | $8.64 | 20.00 |
| 2019-06-30 | 171.56 | $8.86 | 19.37 |
| 2019-03-31 | 169.46 | $7.57 | 22.39 |
| 2018-12-31 | 152.42 | $7.11 | 21.43 |
| 2018-09-30 | 175.99 | $7.44 | 23.64 |
| 2018-06-30 | 161.07 | $7.36 | 21.87 |
| 2018-03-31 | 145.23 | $6.97 | 20.84 |
| 2017-12-31 | 142.97 | $7.84 | 18.24 |
| 2017-09-30 | 130.42 | $8.15 | 16.00 |
| 2017-06-30 | 129.39 | $6.25 | 20.72 |
| 2017-03-31 | 121.19 | $8.58 | 14.12 |
| 2016-12-31 | 108.93 | $7.99 | 13.64 |
| 2016-09-30 | 117.74 | $8.58 | 13.73 |
| 2016-06-30 | 110.68 | $9.16 | 12.09 |
| 2016-03-31 | 98.70 | $7.76 | 12.72 |
| 2015-12-31 | 99.73 | $6.11 | 16.32 |
| 2015-09-30 | 85.49 | $5.46 | 15.64 |
| 2015-06-30 | 90.89 | $4.30 | 21.12 |
| 2015-03-31 | 91.74 | $4.11 | 22.35 |
| 2014-12-31 | 88.55 | $5.21 | 17.01 |
| 2014-09-30 | 72.11 | $5.53 | 13.04 |
| 2014-06-30 | 74.60 | $6.84 | 10.90 |
| 2014-03-31 | 73.49 | $6.73 | 10.92 |
| 2013-12-31 | 69.03 | $6.21 | 11.12 |
| 2013-09-30 | 62.17 | $5.67 | 10.97 |
| 2013-06-30 | 61.12 | $4.72 | 12.96 |
| 2013-03-31 | 58.84 | $5.45 | 10.80 |
| 2012-12-31 | 47.85 | $5.27 | 9.08 |
| 2012-09-30 | 47.77 | $5.45 | 8.76 |
| 2012-06-30 | 45.18 | $5.03 | 8.99 |
| 2012-03-31 | 46.65 | $4.05 | 11.51 |
| 2011-12-31 | 44.62 | $3.83 | 11.64 |
| 2011-09-30 | 43.52 | $4.59 | 9.48 |
| 2011-06-30 | 50.88 | $4.35 | 11.71 |
| 2011-03-31 | 46.78 | $4.59 | 10.18 |
| 2010-12-31 | 49.40 | $4.63 | 10.67 |
| 2010-09-30 | 43.10 | $4.00 | 10.77 |
| 2010-06-30 | 39.12 | $4.39 | 8.92 |
| 2010-03-31 | 45.31 | $4.43 | 10.23 |
| 2009-12-31 | 45.17 | $4.29 | 10.53 |
| 2009-09-30 | 39.76 | $3.90 | 10.18 |
| 2009-06-30 | 40.45 | $3.34 | 12.11 |
| 2009-03-31 | 37.96 | $3.29 | 11.54 |
| 2008-12-31 | 38.41 | $3.06 | 12.55 |
| 2008-09-30 | 44.84 | $3.85 | 11.65 |
| 2008-06-30 | 45.27 | $3.62 | 12.50 |
| 2008-03-31 | 47.64 | $3.08 | 15.46 |
| 2007-12-31 | 46.23 | $3.30 | 14.00 |
| 2007-09-30 | 45.23 | $2.56 | 17.69 |
| 2007-06-30 | 40.93 | $2.78 | 14.74 |
| 2007-03-31 | 42.11 | $2.61 | 16.13 |
| 2006-12-31 | 38.29 | $3.06 | 12.50 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $51.228B | $21.840B |
| Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $104.880B | 22.04 |
| Cardinal Health (CAH) | United States | $54.109B | 20.66 |
| West Pharmaceutical Services (WST) | United States | $25.687B | 42.94 |
| Straumann Holding AG (SAUHY) | Switzerland | $18.592B | 0.00 |
| Align Technology (ALGN) | United States | $10.528B | 16.28 |
| Cooper (COO) | United States | $10.130B | 11.56 |
| Henry Schein (HSIC) | United States | $9.754B | 16.48 |
| Merit Medical Systems (MMSI) | United States | $5.146B | 23.48 |
| DENTSPLY SIRONA (XRAY) | United States | $1.960B | 6.87 |
| CONMED (CNMD) | United States | $1.406B | 9.82 |
| STAAR Surgical (STAA) | United States | $1.125B | 35.07 |
| Pro-Dex (PDEX) | United States | $0.214B | 19.97 |
| Lifevantage (LFVN) | United States | $0.077B | 11.04 |